|1.||Gelb, Michael H: 5 articles (01/2008 - 08/2002)|
|2.||Van Voorhis, Wesley C: 4 articles (01/2008 - 08/2002)|
|3.||Yokoyama, Kohei: 4 articles (01/2008 - 08/2002)|
|4.||Buckner, Frederick S: 4 articles (02/2006 - 08/2002)|
|5.||Yang, Shao H: 3 articles (04/2010 - 10/2006)|
|6.||Young, Stephen G: 3 articles (04/2010 - 10/2006)|
|7.||Beese, Lorena S: 3 articles (09/2008 - 07/2003)|
|8.||Bergo, Martin O: 2 articles (04/2010 - 10/2006)|
|9.||Fong, Loren G: 2 articles (02/2010 - 10/2006)|
|10.||Grellier, Philippe: 2 articles (01/2010 - 10/2005)|
02/01/1998 - "Inhibitors of protein farnesyltransferase are showing sufficient promise in preclinical trials as anti-cancer drugs to warrant widespread interest in the pharmaceutical industry."
09/01/2008 - "Originally designed to block the prenylation of oncogenic Ras, inhibitors of protein farnesyltransferase currently in preclinical and clinical trials are showing efficacy in cancers with normal Ras. "
01/01/2007 - "Since its identification, the enzyme Ras protein farnesyltransferase (PFTase), which catalyzes the initial step of Ras-processing, has been viewed as a most promising target for cancer therapy. "
04/20/2005 - "The andrastins are protein farnesyltransferase inhibitors and are capable of inhibiting the efflux of anticancer drugs from multidrug-resistant cancer cells. "
04/01/2005 - "Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development."
|2.||Progeria (Hutchinson Gilford Syndrome)
02/01/2010 - "Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria."
10/01/2006 - "This concept led to the hypothesis that protein farnesyltransferase inhibitors (FTIs) might ameliorate the disease phenotypes of progeria in mouse models. "
10/01/2006 - "Protein farnesyltransferase inhibitors and progeria."
01/15/2008 - "A new class of 2-oxo-tetrahydro-1,8-naphthyridine-based protein farnesyltransferase inhibitors were synthesized and found to inhibit protein farnesyltransferase from the malaria parasite with potencies in the low nanomolar range. "
10/01/2005 - "Protein farnesyltransferase of Plasmodium falciparum is a potential target in the treatment of malaria for which increased drug resistance is observed. "
06/02/2005 - "Here we show that the enzyme protein farnesyltransferase (PFT) from the malaria parasite Plasmodium falciparum (P. "
01/01/2007 - "Our review focuses on different and important molecular targets for drug design that include proteases that hydrolyze hemoglobin, protein farnesyltransferase, heme detoxification pathway, polyamine pathways, dihydrofolate reductase, artemisinin-based combination therapies (ACTs), etc. Therefore, rational approaches to control malaria targeting metabolic pathways of malaria parasites which are essential for parasites survival are presented."
|4.||African Trypanosomiasis (Nagana)
08/19/2002 - "A series of isothiazole dioxides was synthesized and evaluated as inhibitors of protein farnesyltransferase from the parasite that causes African sleeping sickness (Trypanosoma brucei). "
07/21/2000 - "Protein prenylation occurs in the protozoan that causes African sleeping sickness (Trypanosoma brucei), and the protein farnesyltransferase appears to be a good target for developing drugs. "
|5.||Parasitic Diseases (Parasitic Disease)
01/15/2010 - "Protein farnesyltransferase (FTase) has recently appeared as a new target of parasitic diseases, a field poor in drugs in development. "
02/01/2006 - "Here, current evidence and progress are summarized that support the targeting of protein farnesyltransferase for the treatment of parasitic diseases."
|1.||Proteins (Proteins, Gene)
|4.||geranylgeranyltransferase type-I (protein geranylgeranyltransferase)
|7.||Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)
|8.||Peptide Hydrolases (Proteases)
|1.||Heterologous Transplantation (Xenotransplantation)
|4.||Drug Therapy (Chemotherapy)